Focal Points: | |
 
   Powered by SearchMedica
SearchMedica recommended medical sites    Search Psychiatric Times    Prioritize Results by Publication Date

Clinical News & Knowledge: Schizophrenia
The Muscarinic Hypothesis of Schizophrenia
Since the discovery of dopamine as a neurotransmitter in the late 1950s, schizophrenia has been associated with changes in the dopaminergic system. However, the dopamine hypothesis of schizophrenia cannot explain all the symptoms associated with this disorder. Therefore, research has also focused on the role of other neurotransmitter systems, including glutamate, g-aminobutyric acid, serotonin, and acetylcholine (ACh) in schizophrenia. More>>
Can Atypical Antipsychotics Reduce Suicide Risk in Patients With Schizophrenia?
Suicide is a devastating, tragically frequent outcome for persons with varying psychiatric conditions, including schizophrenia. An estimated 5% to 10% of persons with schizophrenia commit suicide and 20% to 50% attempt suicide during their lifetime.1,2 Patients with schizophrenia have more than an 8-fold increased risk of completing suicide (based on the standardized mortality ratio) than the general population.3 More>>
Medications and Quality of Life With Schizophrenia
The expression "quality of life" is an intuitively familiar and popular concept, and it epitomizes the public's hopes and expectations. In clinical settings, it demands the inclusion of patients' feelings, attitudes, and opinions in medical decision making. More>>
Does Infection Increase Risk of Psychosis and Schizophrenia?
New research is examining the link between schizophrenia/psychosis and select infections affecting the CNS. Two reports investigated this link in children and military personnel in the January 2008 issue of the American Journal of Psychiatry. More>>
New Findings in Early-Onset Schizophrenia
Recently, a number of studies have examined the characteristics of early-onset schizophrenia spectrum disorders and medication treatment for youths with schizophrenia. More>>
Schizophrenia, Metabolic Syndrome, and Antipsychotics
Schizophrenia, a devastating mental illness that affects nearly 2.2 million Americans, is associated with high rates of morbidity and mortality. Individuals with schizophrenia have a 20% shorter life expectancy than the general population. Furthermore, among persons with schizophrenia, there is an increased prevalence of metabolic syndrome characterized by a constellation of risk factors, including insulin resistance, abdominal obesity, dyslipidemia, hyperglycemia, and hypertension, all of which... More>>
Nicotine Dependence in Schizophrenia: Prevalence, Mechanisms, and Implications for Treatment
Each year more than 440,000 people in the United States die of smoking-related illness, and nearly half a billion dollars in health-related economic losses are directly attributable to smoking. More>>
Atypical Antipsychotics for Treatment of Schizophrenia Spectrum Disorders
The number of prescriptions for antipsychotic treatment of teenagers has increased sharply in office-based medical practice. Adolescents with psychotic symptoms frequently present for clinical evaluation, and early-onset schizophrenia spectrum disorders (onset of psychotic symptoms before the age of 18 years) represent an important consideration in the differential diagnosis in these youths More>>
Negative Symptoms in Schizophrenia: The Importance of Identification and Treatment
Schizophrenia is among the top 10 disabling conditions worldwide for young adults. In the United States, the cost of treatment and loss in productivity associated with schizophrenia are estimated to be as high as $60 billion annually. More>>
Schizophrenia: Some Neglected Topics
It is a pleasure to introduce this series of 4 special articles on schizophrenia. As industry support has shaped postgraduate psychiatric education, the quantity of educational programs has grown dramatically while the breadth of topics has not. More>>
Showing 1 - 10 of 74 results.
Page of 8
Article Tools
SearchMedica Search Results